F2G & Shionogi Signal Market Shift with Landmark Antifungal Results

MANCHESTER, UK & OSAKA, JAPAN – June 18, 2026 – In a move sending strong growth signals across the biopharmaceutical landscape, F2G Ltd. and its partner Shionogi today announced positive topline results from a pivotal Phase 3 study. Their investigational drug, olorofim, has demonstrated it is not only as effective as a current standard of care for a life-threatening fungal infection but also significantly safer, positioning it to become the first new class of treatment for the condition in over two decades.

The successful outcome of the global OASIS trial is a landmark achievement in the fight against invasive aspergillosis (IA), a devastating infection that preys on the most vulnerable, immunocompromised patients. For F2G, a clinical-stage biotech, and Shionogi, a Japanese pharmaceutical giant, the data represents a crucial step toward regulatory approval and a potential multi-billion-dollar market, validating their strategic collaboration and signaling a potential new leader in a long-neglected therapeutic area.

A New Weapon for a Deadly Infection

The Phase 3 OASIS study was designed to prove that oral olorofim was "non-inferior" to the current standard, an intravenous regimen of AmBisome® followed by other standard therapies. The trial not only met this primary goal but did so with a remarkable safety advantage. At Day 42, the all-cause mortality rate for patients on olorofim was 23.8%, statistically equivalent to the 24.3% rate in the AmBisome® arm.

The critical differentiator, however, lies in the safety data. The rate of drug-related treatment-emergent adverse events was nearly halved in the olorofim group, at 35.8% compared to a staggering 63.9% for the AmBisome®-based regimen. The difference, the companies noted, was primarily driven by a lower incidence of kidney-related side effects, a well-known and often treatment-limiting toxicity associated with amphotericin B formulations like AmBisome®.

Invasive aspergillosis is a brutal infection caused by a common mold that primarily affects patients whose immune systems are severely weakened, such as those undergoing cancer chemotherapy, organ transplant recipients, and increasingly, critically ill patients in the ICU. With historical mortality rates soaring as high as 80-85% in some populations, the need for effective and tolerable treatments is acute. The OASIS study specifically enrolled patients for whom first-line azole therapies had failed or were unsuitable, a hard-to-treat population with grim prognoses.

“The OASIS topline results add to the growing body of evidence supporting olorofim’s therapeutic potential in a hard-to-treat population with limited antifungal options,” said Dr. Johan Maertens, the study’s Principal Investigator and a Professor of Hematology at University Hospitals Leuven, Belgium. “We’re hopeful this could offer a meaningful alternative for clinicians to treat challenging infections caused by Aspergillus.”

Decoding the Signal: Market Momentum and Regulatory Redemption

These clinical results are a powerful growth signal for the F2G-Shionogi partnership. The global market for invasive aspergillosis therapeutics, valued at approximately $1.62 billion in 2024, is projected to climb to $2.68 billion by 2033. Olorofim, with its novel mechanism, oral formulation, and superior safety profile, is now poised to capture a significant share of this expanding market.

The journey, however, has not been without its challenges. This positive data serves as a form of regulatory redemption for F2G. In June 2023, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for an earlier application based on Phase 2 data, requesting more robust evidence. The successful completion of the Phase 3 OASIS study directly addresses that request, paving a much clearer path to market. F2G has stated its intention to resubmit its application to the FDA by the end of 2026, pointing toward a potential U.S. approval in mid-2027.

“These findings demonstrate the potential for olorofim to serve as a new option for patients with difficult to treat invasive fungal infections,” commented Francesco Maria Lavino, Chief Executive Officer of F2G. The sentiment was echoed by Shionogi, which holds the commercialization rights for Europe and Asia.

Dr. John Keller, Senior Vice President of R&D at Shionogi, called the results "a promising new development in antifungal medicine – an area where patients have been under-served for more than 20 years." He emphasized the clinical challenge posed by renal toxicity in current treatments, suggesting olorofim could offer a transformative solution. This strategic success bolsters Shionogi's established leadership in infectious diseases and promises a significant new revenue stream.

A Breakthrough in the Broader War on Resistance

Beyond the immediate commercial implications, olorofim's success is a crucial development in the global fight against antimicrobial resistance (AMR). Olorofim is the first of a new class of antifungals called orotomides. It works by inhibiting a fungal enzyme, dihydroorotate dehydrogenase (DHODH), that is essential for the pathogen's survival—a mechanism completely distinct from any existing antifungal.

This is critically important as resistance to current drugs, particularly azoles, is on the rise. The widespread use of azoles in agriculture has accelerated the emergence of resistant Aspergillus strains, leaving clinicians with fewer effective options. A drug with a novel mechanism provides a new line of attack against these resistant organisms, a point of major interest for public health bodies like the CDC, which has repeatedly warned about the silent pandemic of fungal resistance.

The drug's oral formulation also represents a major practical advantage. It offers the potential to treat patients outside of the hospital, reducing healthcare costs and improving quality of life compared to the lengthy intravenous infusions required for drugs like AmBisome®.

While other novel antifungals are in development, olorofim's first-in-class status and its proven efficacy and safety in a pivotal Phase 3 trial place it at the forefront of the next generation of fungal infection treatments. F2G and Shionogi now plan to present the full, detailed results from the OASIS study at an upcoming medical congress, which will be closely watched by clinicians, investors, and competitors alike. With regulatory submissions on the horizon in the U.S., Europe, and Asia, these positive results are the clearest signal yet that the two-decade innovation gap in treating this deadly fungal infection is finally closing.